- Specialization
Biotechnologyand 1 more specialization valuesLess
- Scientific Discovery
- Business
Scientific Researchand 2 more business valuesLess
- Biomanufacturing
- Model Development
- Market
Defenseand 1 more market valuesLess
- Life Sciences
- Ecosystem
- AI for science
- Customers
Governmentsand 2 more customers valuesLess
- Enterprises
- Researchers
More details
- Organization type
- Commercial Company
- Ecosystem
- AI for science
- Business
- Scientific Research, Biomanufacturing, Model Development
- Specialization
- Biotechnology, Scientific Discovery
- Market
- Defense, Life Sciences
- Customers
- Governments, Enterprises, Researchers
- Delivery models
- Professional Services, Physical Goods
- Revenue models
- Not classified
- Listing status
- Not classified
- Latest equity round
- Seed
- Reported funding amount
- $10M-$50M
About
Red Queen Bio builds an AI-powered biodefense layer that rapidly designs and manufactures medical countermeasures for emerging biological threats. It works with frontier laboratories and targets governments and the global biopharma industry, differentiating itself through compute-scalable proprietary datasets, advanced AI models, lab automation, reinforcement learning, and on-demand biologics manufacturing.
Market
Red Queen Bio competes in AI-enabled biosecurity and biodefense, addressing the faster evolution of AI-assisted biological threats through threat discovery, countermeasure design, manufacturing, and deployment. Its differentiation is an end-to-end defensive platform combining frontier AI, proprietary datasets, lab automation, reinforcement learning, and rapid drug-countermeasure production, while explicitly avoiding dangerous gain-of-function research; competitors more often emphasize one part of the stack, such as Valthos's real-time threat identification and countermeasure design, SecureBio's AI-risk evaluations, or Concentric's pathogen surveillance.
Red Queen Bio appears to target institutional buyers and partners: frontier AI laboratories, government biodefense and public-health organizations, and biotechnology or pharmaceutical groups responsible for biological-threat preparedness. Its likely buyers are security, biosecurity, R&D, and biodefense leaders rather than individual consumers, with the company explicitly describing partnerships with frontier labs and a focus on US biodefense.
At a Glance
Problem
Red Queen Bio addresses the widening gap between rapidly advancing AI-enabled biological capabilities and the defenses needed to contain them. The company argues that as AI capabilities advance, biological risks can grow exponentially, creating an incentive and resource-allocation problem: defensive capacity must scale alongside the same compute and financing forces driving the capability race. The central use case is to identify AI-enabled biothreats early and prepare medical countermeasures before those threats emerge.
Product / Service
Red Queen Bio is building defensive infrastructure for biology rather than a single therapeutic product. It works with frontier laboratories to map potential AI-enabled biothreats and pre-build countermeasures through a pipeline combining leading AI models, laboratory automation, reinforcement learning, and on-demand biologics manufacturing. The intended benefit is a defense system that can scale directly with compute, allowing biological preparedness to keep pace with AI-driven offensive capabilities.
The delivery model is collaborative and cross-industry: Red Queen Bio says it intends to work with AI labs, biopharma companies, and governments, while operating as a Public Benefit Corporation whose mission is designed to take precedence over any individual partnership.
Market
The company operates in the emerging AI biosecurity and biodefense infrastructure market, at the intersection of frontier AI, biotechnology, biologics manufacturing, and public-sector preparedness. Its stated ecosystem includes frontier AI labs, biopharma, and governments. The available company materials do not name direct competitors, so a specific competitive set cannot yet be established; Red Queen Bio appears to be positioning itself around the broader category of defensive co-scaling for AI-enabled biology.
Red Queen Bio is at an early launch and financing stage. It reports a $15 million seed round led by OpenAI, with participation from Cerberus Ventures, Fifty Years, and Halcyon Futures. The materials describe the launch, funding, and development of its countermeasure pipeline but disclose no revenue, deployed products, or customer metrics, so the evidence supports financing traction rather than demonstrated commercial traction and does not definitively establish revenue status.
Founders & Leadership
Funding History
OpenAI
Recent News
A September 27 Wall Street Journal report said Red Queen Bio had raised $36 million in total to develop antibody drugs against viruses, including potential AI-enabled threats. The report also said the company raised $15 million in 2025.
Reuters reported that OpenAI led Red Queen Bio’s $15 million seed round. The startup, spun out of HelixNano, plans to combine AI models with laboratory experiments to identify emerging biological risks and develop defenses.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
Public materials do not disclose specific pricing or a recurring operating-revenue model. The best-supported model is B2B/B2G partnership and contract work with frontier laboratories, governments, and biopharma organizations, while the company has primarily disclosed venture financing to date, including a $15 million seed round.
Products
Tech Stack
Similar Companies
Competitors
Key Investors
OpenAI, Cerberus Ventures, Fifty Years, Halcyon Futures